glp-1 drug market competition 2025 How to Invest in Drugs: Stocks and Funds to Watch GLP-1 Receptor Agonist Market Size
Description
J Cell Physiol
The FDA has raised alarms about unauthorized and improperly compounded GLP-1 formulations that may contain incorrect ingredients or dosages, creating direct pathways to patient harm
American family physician 94 , 106113 (2016)
Which companies and industries will suffer
This is a specialized scenario requiring expert medical oversight
Ileal release of glucagon-like peptide-1 (GLP-1)
